Perficient: Drug Development

FEBRUARY 15, 2024

These DFS500 amendments signal a crucial shift in the regulatory landscape, emphasizing the imperative for robust governance, risk management, and compliance frameworks across the financial industry. Impacted institutions are subject to significant fines relative to the level of non-compliance identified by the regulators.

Compliance 52

Compliance Licensing Licensing Regulations 52

Perficient: Drug Development

FEBRUARY 15, 2024

The NYSDFS Part 500 amendments signal a crucial shift in the financial services regulatory landscape and underscore the importance of robust governance, risk management, and compliance frameworks. Impacted institutions are subject to significant fines relative to the level of non-compliance identified by the regulators.

Compliance 52

Compliance Regulations Licensing Licensing 52

Perficient: Drug Development

JANUARY 19, 2024

The container technology also supports varying levels of technical acumen, business continuity, security, and compliance. This distribution utilizes licensed API keys, streamlining the process for customers to conveniently retrieve and access these containers in their local registries or incorporate them seamlessly into their CI/CD pipelines.

Compliance 118

Compliance Marketing Licensing Licensing 118

Perficient: Drug Development

JUNE 30, 2025

From licensing and credentialing to technology enablement and book of business transitions, the process is often a bottleneck for growth, especially for RIAs and broker-dealers looking to scale. And for good reason: a poorly executed onboarding process can lead to compliance risks, client attrition, and advisor disengagement.

Compliance 52

Compliance Licensing Licensing International 52

Drug Patent Watch

JANUARY 8, 2025

Some common evergreening techniques include: New formulations or delivery methods Combination drugs New indications or uses Metabolite patents While controversial, these techniques can be powerful tools when used ethically and in compliance with regulatory guidelines. Defending Your Patents Obtaining a patent is only half the battle.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Licensing Licensing 52

The Pharma Data

JULY 2, 2025

Under Birgitte’s guidance, Genmab successfully navigated key licensing agreements, multiple strategic collaborations with leading pharmaceutical companies, and its listing on the Nasdaq Global Select Market.

Compliance 40

Compliance Pharmaceutical Companies Government International 40

Perficient: Drug Development

OCTOBER 27, 2023

SAP Commerce Cloud hosting SmartEdit as CMS (existing components, CMS license, …) Perficient’s SAP Commerce Accelerator When we start a project there are various factors we must consider. Opt for SAP Composable Storefront if you value the reliability and support provided by a solution from SAP.

Compliance 105

Compliance Marketing Licensing Licensing 105

FDA Law Blog: Biosimilars

JANUARY 11, 2024

Some of the other (but not all…) topics of interest at this day-long conference presented by US and Puerto Rico industry thought leaders include: Experiences and Challenges of Puerto Rico State Licensing Internal Investigations: Monitoring, Compliance, Enforcement Actions The State of the Pharmaceutical Industry in Puerto Rico Navigating Global Turbulence: (..)

Pharmaceuticals 59

Pharmaceuticals Licensing Licensing Compliance 59

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Laboratories 81

Laboratories FDA Regulations Licensing 81

Conversations in Drug Development Trends

FEBRUARY 21, 2024

Unflinching attention to detail is required to manage AME study participants In AME studies, our top priority is balancing participant comfort and compliance with high-quality data collection. Here are a few of our lessons learned: 1.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

Drug Target Review

APRIL 5, 2024

For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies. Finding the right CDMO may require significant time and company resources, but CLD sits at the heart of biologics development.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

Drug Target Review

DECEMBER 11, 2024

Additionally, incurred sample reanalysis (ISR) plays a crucial role in validating the precision and reliability of reported analyte concentrations, which is particularly important for toxicological assessments where consistent data is critical for identifying potential safety risks.

International 52

International Laboratories Drugs Pharmacokinetics 52

Perficient: Drug Development

JANUARY 24, 2024

Before I begin, I just want to caveat everything with the fact that HIPAA is a complex regulation open to interpretation, and in the end your legal and compliance teams need to be comfortable with how you handle data and the risk associated with those methods. This is because under the covers it is actually using the same instance.

Licensing 96

Licensing Licensing Production Regulations 96

Perficient: Drug Development

OCTOBER 3, 2024

Support and Compliance: Upgrading ensures continued support from HCL and compliance with industry standards and regulations. Accept the license agreement and click Next. Security Enhancements: Each Upgrade includes security patches and improvements to protect against the latest threats. Click Next.

Packaging 52

Packaging Compliance Licensing Licensing 52

Perficient: Drug Development

SEPTEMBER 26, 2024

Support and Compliance: Upgrading ensures continued support from HCL and compliance with industry standards and regulations. Accept the license agreement and click Next. Security Enhancements: Each Upgrade includes security patches and improvements to protect against the latest threats. Click Next.

Packaging 52

Packaging Compliance Licensing Licensing 52

Advarra

JUNE 14, 2024

A regulatory binder is essential for managing clinical trial documents, ensuring regulatory compliance, and facilitating audits. It organizes critical documents; provides easy access for trial monitors, auditors, and regulatory authorities; and serves as a reference for the research team.

Clinical Trials 40

Clinical Trials Trials Compliance FDA 40

Drug Target Review

AUGUST 9, 2024

3 Patient compliance is a critical but complex challenge, with contributing factors reaching beyond just drug formulation. But there are considerations that can be taken in drug formulation to improve patient compliance and therefore lead to better health outcomes.

Science 59

Science Drugs Compliance Drug Development 59

FDA Law Blog: Biosimilars

JULY 18, 2023

Those include biological products licensed under Biologics License Applications (BLAs), approved drugs under New Drug Applications (NDAs), and generic products under approved Abbreviated New Drug Applications (ANDAs). That leaves 60% that manufacture at least one application product.

FDA 52

FDA Licensing Licensing Laboratories 52

The Pharma Data

DECEMBER 28, 2020

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release.

Licensing 52

Licensing Licensing Compliance Virus 52

Conversations in Drug Development Trends

AUGUST 9, 2024

An import license is necessary for any intellectual property or equipment used during the trial. The NMPA and CDE also require compliance with China’s data protection regulations, including the Personal Information Protection Law.

Trials 80

Trials Clinical Trials Regulations FDA 80

Agency IQ

AUGUST 4, 2023

When the ECDRP is invoked, the MHRA will ensure a product’s compliance with applicable regulatory requirements, but will generally perform a less detailed review of the application, relying in part on the decision taken by the EC. However, labeling requirements depend on the type of license of the medicine. license number.

Packaging 40

Packaging Licensing Licensing Regulations 40

The Pharma Data

AUGUST 20, 2020

“If you can get a CE mark [indicating compliance with the relevant legislation] for a bad test as there is no scrutiny on whether it works, it is just a marketing claim that is registered and we are left in a Wild West of antibody testing. “For drug licensing the onus is on the companies to go through clinical trials.

Clinical Trials 52

Clinical Trials Regulations Doctors Government 52

Perficient: Drug Development

JANUARY 3, 2024

Even if the hosting and licensing costs are close, the operational costs of managing a true SaaS offering vs. what you need to support PaaS makes it even more compelling. HIPAA Compliance is Coming At Perficient, Healthcare is one of our biggest industry verticals. No upgrades to plan for ever again.

Compliance 52

Compliance Marketing Production Licensing 52

The Pharma Data

JANUARY 20, 2021

The company is actively recruiting for highly motivated and dedicated team members across the organization, including customer service, marketing, finance, compliance, and quality. . The company projects it will continue a growth trajectory in 2021 and has experienced significant year over year sales growth since inception.

Production 52

Production Treatment Licensing Licensing 52

PPD

JULY 9, 2024

Most industries have in common the need to meet strict timelines while also achieving quality and compliance standards and staying within budget. And it enables careful motoring of quality and compliance key performance indicators (KPIs), along with greater opportunity to apply time- and cost-saving process improvements.

Compliance 52

Compliance Production Clinical Research Marketing 52

The Premier Consulting Blog

NOVEMBER 20, 2024

This process can be initiated during the review period of the biologics license application (BLA) or new drug application (NDA) prior to approval. Note that pre-approval inspections for biologics are referred to as pre-licensing inspections (PLI).

Small Molecule 52

Small Molecule Drugs FDA Production 52

The Pharma Data

JANUARY 3, 2021

.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales in the U.S.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

Perficient: Drug Development

NOVEMBER 22, 2023

Compliance and Regulation: Azure AD B2C provides compliance with industry regulations such as GDPR and HIPAA, as well as support for authentication standards like OpenID Connect and OAuth 2.0. This makes it easier for businesses to comply with regulatory requirements and ensure the security of user data.

Compliance 52

Compliance Regulations Licensing Licensing 52

Perficient: Drug Development

AUGUST 1, 2023

We tested component functionality, visual design, responsiveness, performance, usability, accessibility, and ADA, HIPAA, and SOC2 compliance. Ultimately, developers need a reliable way to test HTL templates outside of AEM without requiring an AEM license. I longed for a similar tool I could use to test HTL templates outside of AEM.

Engineering 52

Engineering Packaging Licensing Licensing 52

FDA Law Blog: Biosimilars

FEBRUARY 29, 2024

. § 156 or case law that would support extension of the ‘929 patent that claims the product despite revocation of the biologics license application. Moreover, Lilly should explain how a PTE application for a withdrawn “revoked” biologics license application is in compliance with requirements of 37 C.F.R.

FDA 59

FDA Production FDA Approval Licensing 59

The Premier Consulting Blog

NOVEMBER 8, 2022

The FDA response to these inquiries provides essential guidance on how you will proceed : Differences in regulatory process between drug-led and device-led combination products Drug-led Device-led Review focus Review Focus: efficacy, potency, safety — typical drug studies Review Focus: device action, compliance with ISO and other applicable standards (..)

Production 52

Production Efficacy & Potency Packaging Drugs 52

The Pharma Data

APRIL 19, 2022

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance.

Trials 52

Trials Treatment Therapies FDA 52

The Pharma Data

JANUARY 27, 2021

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release.

FDA 52

FDA Synthetic Chemistry Assay Development Treatment 52

The Pharma Data

DECEMBER 20, 2020

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release.

Production 52

Production Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 18, 2021

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release.

Pharmacy 40

Pharmacy Regulations Treatment Licensing 40

FDA Law Blog: Biosimilars

MARCH 4, 2024

Failure to provide notification of a discontinuance or interruption to FDA potentially could, among other things, land a manufacturer on the Drug Shortages: Non-Compliance With Notification Requirement website. blood supply; and, Manufacturers of certain finished drug products marketed without an approved NDA or ANDA.

FDA 59

FDA Production Marketing Drugs 59

Perficient: Drug Development

FEBRUARY 14, 2024

You’ve got compliance training, processes training, training from corporate leadership, onboarding training for new team members and more. Whether you license content from a health library or write your own, people already know where to go and whom to trust for the educational content. And it’s not you. But that’s OK!

Engineering 52

Engineering International Marketing Licensing 52